Kevzara is intended to treat patients with moderate to severe rheumatoid arthritis who do not respond to other treatments. The drug is administered via a subcutaneous injection once every two weeks.
Kevzara will cost $39,000 annually for the 150 milligram and 200 milligram doses. Sanofi and Regneron said this figure marks a 30 percent decrease from the cost of two the rival drugs on the market.
More articles on supply chain:
McKesson 2017 revenue up 4%: 5 things to know
What Trump’s budget proposal means for FDA funding
Baking soda shortage forces hospitals to postpone surgeries, treatments
